China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more ...

Pfizer , Teva and other major drugmakers have failed to persuade a federal judge to disqualify a former prosecutor who is representing private health insurers suing the ​companies after he spearheaded ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

TRENTON, N.J.-The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...